Intravenous immunoglobulin for Guillain-Barré syndrome

Retrospective evaluation of Guillain‐Barre syndrome in children: A single‐center experience

“…This was attributed to the shorter duration of IVIG treatment in patients with more severe clinical findings. The duration of IVIG administration was also seen not to affect the long‐term prognosis, which was consistent with the literature 36 …”

Retrospective evaluation of Guillain‐Barre syndrome in children: A single‐center experience

“…This was attributed to the shorter duration of IVIG treatment in patients with more severe clinical findings. The duration of IVIG administration was also seen not to affect the long‐term prognosis, which was consistent with the literature 36 …”

Concurrent Pneumocystis jirovecii pneumonia and Guillain-Barre syndrome after surgery and adjuvant chemoradiotherapy for stage IIIA lung adenocarcinoma: a case report and literature review

“…Cerebrospinal fluid and electrophysiological findings were consistent with GBS, predominantly an axonal variant. Axonal subtypes, cranial nerve involvement, rapid progression and the need for mechanical ventilation have been associated with more severe disease and poorer prognosis, which supports early ICU management, IVIG or plasma exchange, and active rehabilitation [41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60].…”

European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome

“…This small study did not observe significant differences in time to regain unaided walking nor in the secondary outcome measures (low certainty evidence). TRFs were more frequently found in the 2‐day regimen (5/23) as compared with the 5‐day (0/23) IVIg regimen 180,198 . The TF considered there is too little evidence to support the use of a 2‐day IVIg regimen. High versus low IVIg dose : One study investigated lower dose IVIg (3 days 0.4 g/kg) versus higher dose IVIg (6 days 0.4 g/kg) in 39 GBS patients with contra‐indications for PE 180,199 .…”

“…TRFs were more frequently found in the 2‐day regimen (5/23) as compared with the 5‐day (0/23) IVIg regimen 180,198 . The TF considered there is too little evidence to support the use of a 2‐day IVIg regimen. High versus low IVIg dose : One study investigated lower dose IVIg (3 days 0.4 g/kg) versus higher dose IVIg (6 days 0.4 g/kg) in 39 GBS patients with contra‐indications for PE 180,199 . Patients treated with the high‐dose regimen had a non‐significant faster improvement in time to walking with assistance (low certainty evidence).…”

“…There are Cochrane Systematic Reviews of the effects of plasma exchange (PE), 179 Intravenous Immunoglobulin (IVIg), 180 corticosteroids 181 and other treatments for GBS 182 . Most RCTs have been conducted in GBS patients unable to walk unaided (GBS‐DS grade 3 or more).…”

Retrospective evaluation of Guillain‐Barre syndrome in children: A single‐center experience

“…This was attributed to the shorter duration of IVIG treatment in patients with more severe clinical findings. The duration of IVIG administration was also seen not to affect the long‐term prognosis, which was consistent with the literature 36 …”

Concurrent Pneumocystis jirovecii pneumonia and Guillain-Barre syndrome after surgery and adjuvant chemoradiotherapy for stage IIIA lung adenocarcinoma: a case report and literature review

“…Cerebrospinal fluid and electrophysiological findings were consistent with GBS, predominantly an axonal variant. Axonal subtypes, cranial nerve involvement, rapid progression and the need for mechanical ventilation have been associated with more severe disease and poorer prognosis, which supports early ICU management, IVIG or plasma exchange, and active rehabilitation [41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60].…”

European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome

“…This small study did not observe significant differences in time to regain unaided walking nor in the secondary outcome measures (low certainty evidence). TRFs were more frequently found in the 2‐day regimen (5/23) as compared with the 5‐day (0/23) IVIg regimen 180,198 . The TF considered there is too little evidence to support the use of a 2‐day IVIg regimen. High versus low IVIg dose : One study investigated lower dose IVIg (3 days 0.4 g/kg) versus higher dose IVIg (6 days 0.4 g/kg) in 39 GBS patients with contra‐indications for PE 180,199 .…”

“…TRFs were more frequently found in the 2‐day regimen (5/23) as compared with the 5‐day (0/23) IVIg regimen 180,198 . The TF considered there is too little evidence to support the use of a 2‐day IVIg regimen. High versus low IVIg dose : One study investigated lower dose IVIg (3 days 0.4 g/kg) versus higher dose IVIg (6 days 0.4 g/kg) in 39 GBS patients with contra‐indications for PE 180,199 . Patients treated with the high‐dose regimen had a non‐significant faster improvement in time to walking with assistance (low certainty evidence).…”

“…There are Cochrane Systematic Reviews of the effects of plasma exchange (PE), 179 Intravenous Immunoglobulin (IVIg), 180 corticosteroids 181 and other treatments for GBS 182 . Most RCTs have been conducted in GBS patients unable to walk unaided (GBS‐DS grade 3 or more).…”

Retrospective evaluation of Guillain‐Barre syndrome in children: A single‐center experience

“…This was attributed to the shorter duration of IVIG treatment in patients with more severe clinical findings. The duration of IVIG administration was also seen not to affect the long‐term prognosis, which was consistent with the literature 36 …”

Concurrent Pneumocystis jirovecii pneumonia and Guillain-Barre syndrome after surgery and adjuvant chemoradiotherapy for stage IIIA lung adenocarcinoma: a case report and literature review

“…Cerebrospinal fluid and electrophysiological findings were consistent with GBS, predominantly an axonal variant. Axonal subtypes, cranial nerve involvement, rapid progression and the need for mechanical ventilation have been associated with more severe disease and poorer prognosis, which supports early ICU management, IVIG or plasma exchange, and active rehabilitation [41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60].…”

European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome

“…This small study did not observe significant differences in time to regain unaided walking nor in the secondary outcome measures (low certainty evidence). TRFs were more frequently found in the 2‐day regimen (5/23) as compared with the 5‐day (0/23) IVIg regimen 180,198 . The TF considered there is too little evidence to support the use of a 2‐day IVIg regimen. High versus low IVIg dose : One study investigated lower dose IVIg (3 days 0.4 g/kg) versus higher dose IVIg (6 days 0.4 g/kg) in 39 GBS patients with contra‐indications for PE 180,199 .…”

“…TRFs were more frequently found in the 2‐day regimen (5/23) as compared with the 5‐day (0/23) IVIg regimen 180,198 . The TF considered there is too little evidence to support the use of a 2‐day IVIg regimen. High versus low IVIg dose : One study investigated lower dose IVIg (3 days 0.4 g/kg) versus higher dose IVIg (6 days 0.4 g/kg) in 39 GBS patients with contra‐indications for PE 180,199 . Patients treated with the high‐dose regimen had a non‐significant faster improvement in time to walking with assistance (low certainty evidence).…”

“…There are Cochrane Systematic Reviews of the effects of plasma exchange (PE), 179 Intravenous Immunoglobulin (IVIg), 180 corticosteroids 181 and other treatments for GBS 182 . Most RCTs have been conducted in GBS patients unable to walk unaided (GBS‐DS grade 3 or more).…”